Speaking of Wired and science, their look into Sergey Brin and his investments in Parkinson research is worth your time:

Many philanthropists have funded research into diseases they themselves have been diagnosed with. But Brin is likely the first who, based on a genetic test, began funding scientific research in the hope of escaping a disease in the first place.

Two things stuck with me.

Despite the inane Gattaca-inspired fear over the implications of genetic testing, the march towards using our genes as scientific palm readers is progressing:

People told that they were at dramatically higher risk for developing Alzheimer’s later in life seemed to process the information and integrate it into their lives, often choosing to lead more healthy lifestyles.

Second is the notion of applying raw computing power to large data sets to mine insights into disease:

It’s hard to overstate the difference between this approach and conventional research. “Traditionally, an experiment with 10 or 20 subjects was big,” says the Parkinson’s Institute’s Langston. “Then it went up to the hundreds. Now 1,000 subjects would be a lot—so with 10,000, suddenly we’ve reached a scale never seen before. This could dramatically advance our understanding.”